Search results
Showing 401 to 450 of 8905 results
Learn about NICE's proportionate approach to technology appraisals, which aims to streamline the evaluation process for new health technologies, ensuring timely access to innovative treatments while maintaining rigorous standards.
Charging procedure for NICE technology appraisal and highly specialised technologies evaluations
After four years of transformational leadership, NICE CEO Dr Sam Roberts will step down at the end of the year to support her children through a difficult time.
Fees for technology appraisals and highly specialised technologies
NICE fees for technology appraisals and highly specialised technologies
Agenda and papers of the NICE public board meeting on 16 December 2022
Agenda and papers of the NICE public board meeting on 22 September
Agenda and papers of the NICE public board meeting on 22 July
Agenda and papers of the NICE public board meeting on 25 May 2022
Agenda and papers of the NICE public board meeting on 17 May 2023
Agenda and papers of the NICE public board meeting on 19 July 2023
Agenda and papers of the NICE public board meeting on 20 May 2025
People have the right to be able to make informed decisions about their care. Our guidance should be taken into account when making decisions with them.
Agenda and papers of the NICE public board meeting on 21 September 2023
Agenda and papers of the NICE public board meeting on 13 December 2023
Agenda and papers of the NICE public board meeting on 15 May 2024
Agenda and papers of the NICE public board meeting on 17 July 2024
NICE's equality, diversity, and inclusion roadmap and annual action plan - committed to creating a forward-looking, positive work culture where everyone can thrive.
Agenda and papers of the NICE public board meeting on 25 September 2024
Agenda and papers of the NICE public board meeting on 11 December 2024
The principles that guide the development of NICE guidance and standards.
Cenobamate for treating focal onset seizures in epilepsy (TA753)
Evidence-based recommendations on cenobamate (Ontozry) for treating focal onset seizures with or without secondary generalised seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least 2 antiseizure medicines.
Early value assessment (EVA) guidance on digital front door technologies to gather service user information for NHS Talking Therapies for anxiety and depression assessments.
Agenda and papers of the NICE public board meeting on 17 March 2022
The benefits from donanemab (also called Kisunla and made by Eli Lilly) and lecanemab (also called Leqembi and made by Eisai) - remain too small to justify the additional cost to the NHS, one of our independent committees has concluded following consultation.
Some people with cystic fibrosis are set to benefit from a new once-daily triple therapy treatment, following NICE's recommendation of Alyftrek in final draft guidance published today.
We're working with colleagues to ensure that virtual wards are used in a way that maximises the value for patients and the NHS.
A step-by-step timeline of the process we used to develop single technology appraisals (STA).
NICE is unable to make a recommendation on letermovir (Prevymis) for preventing cytomegalovirus infection after a kidney transplant in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1082
NICE is unable to make a recommendation on lisocabtagene maraleucel (Breyanzi) after 1 systemic treatment in adults when a stem cell transplant is unsuitable. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1083
NICE is unable to make a recommendation on idecabtagene vicleucel (Abecma) for treating relapsed or refractory multiple myeloma after 2 to 4 treatments in adults. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1084
Fruquintinib for previously treated metastatic colorectal cancer (TA1079)
Evidence-based recommendations on fruquintinib (Fruzaqla) for previously treated metastatic colorectal cancer in adults.
Cardiovascular risk assessment and lipid modification (QS100)
This quality standard covers identifying and assessing cardiovascular risk in adults without cardiovascular disease, and treatment to prevent primary and secondary cardiovascular disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS100Show all sections
Sections for QS100
- Quality statements
- Quality statement 1: Identifying adults who are likely to be at high risk
- Quality statement 2: Diet and lifestyle advice for primary prevention
- Quality statement 3: Lipid-lowering treatment for primary prevention
- Quality statement 4: Assessing response to lipid-lowering treatment
- Quality statement 5: Secondary prevention of cardiovascular disease
- Update information
- About this quality standard
Read NICE's statement on modern slavery and human trafficking.
How NICE International is supporting evidence-based decision-making through the Regulatory Partnership for Growth Fund
Ask an expert from NICE International, part of the UK's National Institute for Health and Care Excellence, to speak at a healthcare event in your country
Get expert advice and support from NICE International, part of the UK's National Institute for Health and Care Excellence, for a project in your country
Tools for building or evaluating a medtech evidence base with NICE
Our indicators measure outcomes that reflect the quality of care or processes linked by evidence to improved outcomes.
The Office for Digital Health strives to accelerate NICE's efforts to deliver innovation to the health and care system.
Home Implementing NICE guidance Social care...
Home About us...
Information about NICE's gender pay gap data for the 12 months leading up to 31 March 2025.
Thousands could benefit from first immunotherapy for severe birch tree pollen allergy
We have recommended the first under-the-tongue tablet immunotherapy shown to build long-term tolerance to allergens, which could help up to 27,000 people in England with moderate to severe birch tree pollen allergies.
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
NICE provisionally recommends leadless implantable pacemaker in draft guidance
A procedure for people with slow heart rhythms could be used more widely after it was recommended for NHS use in draft guidance.
Find guidance, advice and information for health, public health and social care professionals.
Help make a difference on behalf of the people most affected by our recommendations on our voluntary and community sector forum.
Thousands more breast cancer patients to benefit from new NHS treatment
NICE approves ribociclib combination therapy to help prevent cancer returning in early-stage disease.
People can comment on our guidance at specific stages in its development.
People can comment on our guidance at specific stages in its development.